Dapu Biotech

The company's business model is centered on providing complete solutions that integrate the development and production of its core technologies. ThunderBio develops and manufactures platforms for digital PCR systems, single-cell omics, and high-throughput screening. These products serve clients in the biopharmaceutical and clinical medicine sectors. Applications for its technology include cancer research, early cancer screening, non-invasive prenatal diagnosis, targeted therapy, and high-throughput drug and antibody screening.

ThunderBio's core technology utilizes droplet-based microfluidics to rapidly divide a reaction system into numerous micron-level droplets, allowing for independent reactions within each one. This approach enhances the throughput and sensitivity of biochemical tests. Its product lineup features a digital PCR system, a single-cell analysis system, and a high-throughput sorting system. The company has secured significant funding, including a Series B round in January 2024 for $14.1 million, bringing its total raised capital to over $15 million.